New drug aims to supercharge immune system against tough cancers

NCT ID NCT06582017

Recruiting now Disease control Sponsor: Nammi Therapeutics Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new drug called QXL138AM in about 100 people with advanced solid tumors (like ovarian, pancreatic, or lung cancer) or multiple myeloma. The drug is designed to help the immune system attack cancer cells. The main goal is to check safety and find the right dose, with a secondary look at whether it shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QXL138AM (an antibody fused with an immune protein to target and attack cancer cells)
What this could lead to: If it works, this could point toward a new treatment option for several hard-to-treat cancers, including ovarian, pancreatic, and multiple myeloma.
What could go wrong: This is a very early, first-in-human trial with only 100 participants. The drug may not be safe or effective, and side effects could be serious. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm digestive system cancer digestive system neoplasm hepatocellular carcinoma lung cancer lung neoplasm malignant pancreatic neoplasm ovarian cancer pancreatic neoplasm plasma cell myeloma prostate cancer renal cell carcinoma transitional cell carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER GASTROINTESTINAL CANCER HEPATOCELLULAR CARCINOMA LUNG CANCER OVARIAN CANCER PANCREAS CANCER PROSTATE CANCER RENAL CELL CARCINOMA UROTHELIAL CARCINOMA

Contacts and locations

Locations

Cedars-Sanai Medical Center
RECRUITING

Los Angeles, California, 90048, United States
Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer
RECRUITING

Los Angeles, California, 90048, United States
Emory University - Winship Cancer Institute
RECRUITING

Atlanta, Georgia, 30322, United States
Froedtert Hospital & the Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States
Hoag Memorial Hospital Presbyterian
RECRUITING

Newport, California, 92663, United States
New York Cancer & Blood Specialists
RECRUITING

New York, New York, 11967, United States
START San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
Sarah Cannon Research Institute - Denver DDU
RECRUITING

Denver, Colorado, 80218, United States
University of Rochester - Wilmot Cancer Institute
RECRUITING

Rochester, New York, 14642, United States
University of Southern California
RECRUITING

Los Angeles, California, 90033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.